News Center

News Center

News Center

DualityBio’s Partner Avenzo Therapeutics to Present Preliminary Phase 1 Study Results of AVZO-1418, a Potentially Differentiated EGFR/HER3 Bispecific Antibody-Drug Conjugate, at the 38th EORTC-NCI-AACR Symposium

2024-11-26

Duality Biologics Announces Expansion of Adcendo ApS Collaboration Through Option Exercise of Strategic License Agreement
2024-11-08

11th Annual World ADC Awards - Proposal Sheet ML
2024-11-04

DualityBio's First-in-Class ADC Drug DB-2304 for Autoimmune Diseases Completes First Global Patient Dosing in Phase I Clinical Trial
2024-09-09

DualityBio's Next-Generation Bispecific ADC DB-1419 Receives FDA IND Approval and Completes First Global Patient Dosing

«
1
2
3
4
5
6
7
»

Scan the code to follow DualityBio official wechat

Phone：021-2601 8730

Address：Full floor, 11th floor, tower a, Datang International Plaza,China

Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area, Shanghai